FDA Approves FOSAPREPITANT — Fresenius Kabi USA, LLC

Fresenius Kabi USA, LLC has received approval for the intravenous formulation of fosaprepitant dimeglumine (ANDA 206,197), which provides an alternative supply for branded emergency contraception. This approval is expected to strengthen the company's market presence in the antiemetic space, particularly as it offers a generic option for healthcare facilities seeking to mitigate drug shortages.